Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT03382912 · TERMINATED
Trial details
- NCT number
- NCT03382912
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-22
- Primary completion
- 2019-08-28
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.